These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29069010)

  • 1. Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
    Liu Y; Qi M; Hou S; Shao L; Zhang J; Li Y; Liu Q
    Medicine (Baltimore); 2017 Oct; 96(43):e8345. PubMed ID: 29069010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Tang LN; He AN; Shen Z; Yao Y
    Lung; 2011 Dec; 189(6):437-43. PubMed ID: 21986852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.
    Liu Y; Liu Y; Fan ZW; Li J; Xu GG
    Eur J Clin Pharmacol; 2015 May; 71(5):541-7. PubMed ID: 25753291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
    Ma W; Xu M; Liu Y; Liu H; Huang J; Zhu Y; Ji LJ; Qi X
    Int J Cancer; 2015 Jul; 137(2):409-19. PubMed ID: 25471638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
    Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Shi Y; Song Y
    Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):e7-e15. PubMed ID: 23177099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
    Ahn JS; Lee KH; Sun JM; Park K; Kang ES; Cho EK; Lee DH; Kim SW; Lee GW; Kang JH; Lee JS; Lee JW; Ahn MJ
    Lung Cancer; 2013 Dec; 82(3):455-60. PubMed ID: 24075125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.
    Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
    Am J Ther; 2017 May; 24(3):e351-e360. PubMed ID: 26280290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
    Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
    J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
    Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
    J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
    Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Matsumoto S; Kohno T; Tsuta K; Tsuchihara K; Ishii G; Nomura S; Sato A; Ohtsu A; Ohe Y; Goto K
    Lancet Respir Med; 2017 Jan; 5(1):42-50. PubMed ID: 27825616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
    J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang X; Qin Y; Li H; Bai C; Zhu T; Xu J; Wu C; Wu M; Wang C; Song H; Wei L; He J
    Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Br J Clin Pharmacol; 2013 Apr; 75(4):919-30. PubMed ID: 22882307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.
    Huo Z; Yu S; Hong S; Cao X; Xiu L; Liao Z; Li Y; Xiao H
    Onco Targets Ther; 2016; 9():3621-31. PubMed ID: 27382300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Pan G; Ke S; Zhao J
    Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
    Tao L; Zhuo W; Yang F; Zhu B
    Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):172-8. PubMed ID: 22429581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.